Galleri blood test detects fifty cancers early via cfDNA analysis for adults 50+ with no symptoms, though not a standard ...

The American Cancer Society recommends people at average risk of colorectal cancer start screening at age 45, now several ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

It is a non-invasive colorectal cancer screening test that uses next-generation sequencing (NGS) technology to detect abnormal DNA methylation patterns in stool samples. These methylation changes ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early ...

Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the ...

What's been going on in the life sciences world this week? Check out Week in Brief for an overview of the biggest news.

Also Read: Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test ... is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a ...